Document Type : Letters to the Editor

Authors

1 Sanitation 1, Medical Academic Center, Bangkok, Thailand

2 Hainan Medical University, China

3 Faculty of Medicine, University of Nis, Serbia

4 Joseph Ayobabalola University, Nigeria

Abstract

Ebola virus disease is the important emerging disease in Africa. This infection is deadly and has the main clinical feature as an acute hemorrhagic fever. The main hematological alteration in this infection is the platelet change. However, the change in other hematological parameters should be mentioned. 

Keywords

Dear Editor-in-Chief

Ebola virus disease is the important emerging disease in Africa. This infection is deadly and has the main clinical feature as an acute hemorrhagic fever. The main hematological alteration in this infection is the platelet change. However, the change in other hematological parameters should be mentioned.

Here, the authors analyzed the available data on hemoglobin level among the hospitalized patients with Ebola virus disease in reported cases. Of interest, from all available reports (7 reports, 20 patients) on hospitalized patients with Ebola virus disease (1 – 6), there is no report on anemia on the first visit or hospitalization day. However, based on 2 reports (2 reports, 3 patients) with available data on following up hemoglobin level during hospitalization, all patients developed anemia.

The anemia can be observed between the 17 and 20 days of illness (average = 18 + 1.7 days). The decreased quantity of hemoglobin level from hospitalization day to the day when anemia is observed is between 2 and 6.9 g/dL (average = 4.6 + 2.5 g/dL). Based on these data, anemia can be the observed laboratory change in the cases with Ebola virus disease.

It is suggested that hemoglobin level should be regularly monitored and the risk period for anemic problem is on the 2 to 3 weeks of illness. Indeed, the etiology of anemia embraces  many causes  and it might be difficult to postulate Ebola causing anemia.  Further studies to find the exact pathophysiology of anemia in the course of illness is suggested.

  1. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 2014;371(15):1418-25.
  2. Fletcher TE, Brooks TJ, Beeching NJ. Ebola and other viral haemorrhagic fevers. BMJ 2014; 349:g5079.
  3. Gostin LO, Lucey D, Phelan A. The Ebola epidemic: a global health emergency. JAMA 2014; 312(11):1095-6.
  4.  Green A. WHO and partners launch Ebola response plan. Lancet 2014; 384:481.
  5. Kraft CS, Hewlett AL, Koepsell S, Winkler AM, Kratochvil CJ, Larson L, et al. The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States. Clin Infect Dis 2015; 61(4):496-502.
  6. Lyon GM, Mehta AK, Varkey JB, Brantly K, Plyler L, McElroy AK, et al. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med 2014;371(25):2402-9